On this page
Overview
Product & regulatory status
US prescription products exist; confirm the indication and formulation on your own medicine label. Compounded preparations are not FDA-approved finished products.
GLP-1 signaling
Semaglutide acts through GLP-1 receptors, affecting glucose regulation and appetite. Its different products have different approved uses. The medicine name alone does not identify which indication, formulation, or instructions apply. [1]
What the evidence shows
Weight-management evidence
A randomized trial in adults with overweight or obesity studied weight change with this medicine alongside lifestyle intervention. Results apply to the studied population and treatment, not every formulation. [2]
STEP 1 · what was measured
The 68-week randomized STEP 1 trial included 1,961 adults with overweight or obesity, without diabetes, alongside lifestyle intervention. Mean weight change was −14.9% with semaglutide and −2.4% with placebo. These are group averages for a particular study, not a personal forecast or a result transferable to every formulation. [2]
What remains unknown
A group average does not predict an individual result. Other indications and formulations need their own evidence.
Safety
Important medicine precautions
Patient information includes a thyroid-tumor warning and precautions about pancreatitis, gallbladder problems, dehydration, and low blood sugar with some other medicines. Review the full information with your clinician. [1]
Check the product and presentation
Injection products have product-specific storage and device instructions. Do not freeze the medication. Check the current leaflet for your exact pen or vial, especially after opening or a temperature excursion. [1]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [3]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [4]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
What should I ask when comparing products?
A group average does not predict an individual result. Other indications and formulations need their own evidence.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- Semaglutide InjectionMedlinePlus · patient medicine information
- Once-Weekly Semaglutide in Adults with Overweight or Obesity2021 · randomized human trial · PMID 33567185
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.